Background/purpose Rheumatoid arthritis (RA) is the most common inflammatory chronic joint disorder. Interleukin-1 (IL-1) family members play a key part in the pathogenesis of RA. Among the IL-1 cytokine family members, IL-18 is a proinflammatory cytokine, which modulates Th1 development and induces angiogenesis. The authors previously described a regulation of TNFα-induced-IL-18 bioactivity by blocking the ERK pathway. Here, the authors focused on modulation of TNFα-induced-IL-18 bioactivity by reduction of caspase-1 expression.
Method Caspase-1 expression in RA synovial fibroblasts treated with TNFα was assessed by qRT-PCR and Western blot. The critical pathways for TNFα-induced caspase-1 expression were determined by using chemical inhibitors: pyrrolidine dithiocarbamate (PDTC; a nuclear factor κ-light-chain-enhancer of activated B cells (NFκB) inhibitor; 200 μM), MAPK inhibitors (ERK1/2, PD98059; p38, SB202190; or JNK2, SP600125; 10 μM), or AG-490 (a Jak2 inhibitor; 10 μM) followed by TNFα stimulation. Caspase-1 expression was determined by qRT-PCR and Western blot. Immunofluorescence (IF) staining was performed to check IL-18 production induced by TNFα with or without preinhibition of ERK1/2 or JAK2 by using antibody recognised immature and mature IL-18. IL-18 functional activity was assessed using an IL-18 bioactivity assay using KG-1 cells and culture supernatants.
Result TNFα induced RA synovial fibroblast caspase-1 expression at the mRNA and protein levels in a time-dependant manner (p<0.05; n≥6 patients). Blocking the Jak2 pathway reduced TNFα-induced-caspase-1 expression at the transcriptional and protein level by approximately 60% and 40%, respectively (p<0.05; n≥4). Blocking NFκB, ERK1/2, JNK or p38 pathways had no effect on TNFα-induced-caspase-1 mRNA expression. The authors then confirmed by IF that TNFα-induced IL-18 and investigated roles of ARK1/2 and JAK2 pathways. Blocking the ERK1/2 pathway dramatically decreased IL-18 expression induced by TNFα. However, blocking the JAK2 pathway, TNFα induced intracytoplasmic granularly IL-18 expression suggesting a defect of caspase-1. Finally, blocking the Jak2 pathway, the authors observed a reduction of IL-18 bioactivity by 52% in RA synovial fibroblasts.
Conclusion These results show a new way to block TNFα-induced-IL-18 bioactivity by blocking capase-1. These data provide a new role for the Jak2 pathway in RA patients and emphasise the use of Jak inhibitors as a new therapeutic option in the management of RA.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.